Not finding it? Sign in to also search OpenAlex live.
-
Selinexor Efficacy and Safety Are Independent of Renal Function in Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL): A Post-Hoc Analysis from the Pivotal Phase 2b Sadal Study
Michael W. Schuster, Miguel Ángel Canales, Jason R. Westin, Josée M. Zijlstra, George Follows, Reem Karmali, +32 more
3citations -
Effect of Age on the Efficacy and Safety of Single Agent Oral Selinexor in Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL): A Post-Hoc Analysis of the Sadal Pivotal Study
Michael W. Schuster, Miguel Ángel Canales, Jason R. Westin, Josée M. Zijlstra, George Follows, Reem Karmali, +32 more
3citations -
Health-Related Quality of Life and Utility Outcomes with Selinexor in Relapsed/refractory Diffuse Large B-Cell Lymphoma2021 Future Oncology article Economics, Econometrics and Finance Health Systems, Economic Evaluations, Quality of Life Open access
Jatin J. Shah, Sharon Shacham, Michael G. Kauffman, Patrick Daniele, D. Tomaras, Gabriel Tremblay, +30 more
12citations -
The nuclear export inhibitor selinexor improves kidney function in a rat model of focal segmental glomerulosclerosis2025 American Journal of Physiology-Renal Physiology article Medicine Renal Diseases and Glomerulopathies Open access
Yingying Gao, Ina Verena Martin, Ute Raffetseder, Xiyang Liu, Anna Leitz, Marcus Johannes Moeller, +8 more
3citations -
Selinexor in patients with relapsed or refractory diffuse large B-cell lymphoma (SADAL): a single-arm, multinational, multicentre, open-label, phase 2 trial2020 The Lancet Haematology article Medicine Lymphoma Diagnosis and Treatment Open access cited by 2 patents
Nagesh Kalakonda, Marie Maerevoet, Federica Cavallo, George Follows, Andre Henri Goy, Joost S.P. Vermaat, +30 more
345citations -
Comparison of the Effectiveness and Safety of the Oral Selective Inhibitor of Nuclear Export, Selinexor, in Diffuse Large B Cell Lymphoma Subtypes2021 Clinical Lymphoma Myeloma & Leukemia article Medicine Lymphoma Diagnosis and Treatment Open access
Olivier Casasnovas, George Follows, Josée M. Zijlstra, Joost S.P. Vermaat, Nagesh Kalakonda, Sylvain Choquet, +26 more
9citations -
Effect of Prior Therapy and Disease Refractoriness on the Efficacy and Safety of Oral Selinexor in Patients with Diffuse Large B-cell Lymphoma (DLBCL): A Post-hoc Analysis of the SADAL Study2021 Clinical Lymphoma Myeloma & Leukemia article Medicine Lymphoma Diagnosis and Treatment Open access
Michael K. Schuster, Josée M. Zijlstra, Olivier Casasnovas, Joost S.P. Vermaat, Nagesh Kalakonda, Andre Henri Goy, +28 more
5citations -
PCN325 Health Utility in Relapsed/Refractory Diffuse Large B-Cell Lymphoma (RR-DLBCL) Patients - Results of a Phase II Trial with ORAL Selinexor2020 Value in Health conference-abstract Economics, Econometrics and Finance Health Systems, Economic Evaluations, Quality of Life Open access
Olivier Casasnovas, Patrick Daniele, Marie Maerevoet, J. M. Zijlstra, George Follows, Joost S.P. Vermaat, +23 more
1citations
14 results